Rubius Therapeutics, Inc
RUBY
RUBY was delisted on the 6th of March, 2023.
76 hedge funds and large institutions have $771M invested in Rubius Therapeutics, Inc in 2019 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 29 increasing their positions, 22 reducing their positions, and 11 closing their positions.
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
32% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 22
22% more capital invested
Capital invested by funds: $632M → $771M (+$139M)
1% more funds holding
Funds holding: 75 → 76 (+1)
9% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 11
100% less call options, than puts
Call options by funds: $3K | Put options by funds: $950K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
+$20.5M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$13.1M |
| 3 |
AFM
Abbot Financial Management
Andover,
Massachusetts
|
+$5.45M |
| 4 |
EC
EcoR1 Capital
San Francisco,
California
|
+$2.57M |
| 5 |
Millennium Management
New York
|
+$1.79M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AllianceBernstein
Nashville,
Tennessee
|
-$26.8M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$3.86M |
| 3 |
Jennison Associates
New York
|
-$3.41M |
| 4 |
Alkeon Capital Management
New York
|
-$3.14M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$712K |
RUBY Hedge Fund Activity: Q4 2019 in Review
76 of the 5,092 institutional investors tracked by Wall St. Rank reported a position in Rubius Therapeutics, Inc (RUBY) for Q4 2019, worth a combined $771M — up 22% from $632M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new RUBY positions and 11 closed out — a net gain of 1 holder — while 29 added to existing stakes and 22 trimmed.
The largest buyer was Capital World Investors, adding an estimated $20.5M. The largest seller was AllianceBernstein, cutting an estimated $26.8M.
- 76 institutional investors held Rubius Therapeutics, Inc (RUBY) as of Q4 2019, up from 75 in Q3 2019.
- Funds reported $771M of Rubius Therapeutics, Inc stock for Q4 2019, up 22% quarter-over-quarter.
- 12 funds opened new Rubius Therapeutics, Inc positions in Q4 2019 and 11 closed out, a net change of +1 holder.
- The largest Rubius Therapeutics, Inc buyer in Q4 2019 was Capital World Investors, an estimated $20.5M added.
- The largest Rubius Therapeutics, Inc seller in Q4 2019 was AllianceBernstein, an estimated $26.8M sold.
Based on aggregated 13F filings for Q4 2019.